IGC Pharma (IGC) announced the addition of Kerwin Medical Center in Dallas, Texas as a clinical site in the Company’s Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s disease. The Company recently reported approximately 80% enrollment in CALMA and continues to advance toward enrollment completion.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGC:
- IGC Pharma Secures New Promissory Note Financing Agreements
- IGC Pharma secures Colombian authorization for psilocybin research
- IGC Pharma reaches 80% enrollment in Phase 2 CALMA trial
- IGC announces activation of new clinical trial sate for Phase 2 CALMA trial
- IGC Pharma Launches National Media Partnership to Boost Visibility